Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.
Latest from Jessica Merrill
“We are not going back to Pasteur,” Pfizer CEO Albert Bourla said, criticizing the US government’s current anti-vaccine rhetoric.
“We are not going back to Pasteur,” CEO Albert Bourla said, criticizing the US government’s current anti-vaccine rhetoric.
The big pharma’s 2026 revenue guidance of $59.5bn-$62.5bn is roughly flat with what is expected in 2025, and EPS guidance is below analyst expectations.
The nasal spray was approved by the US FDA as a rapid acting treatment for acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT).
Subsidiary Pulmovant plans to report Phase II data in pulmonary hypertension associated with interstitial lung disease in 2026, one of several programs highlighted during an investor event.
The selective estrogen receptor degrader reduced the risk of invasive disease recurrence or death by 30% in ER-positive early stage breast cancer.